Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron in Recurrent Ovarian Cancer
NCT07261683Phase 2Recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, mirabegron in ovarian cancer, sponsored by Obstetrics and Gynecology Hospital of Fudan University. Started Dec 2025; status: recruiting.
02
Drugs
pembrolizumabmirabegron
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07261683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261683.